U.S. Markets closed

See Why RenovoRx Stock Is Shooting Higher On Tuesday

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • The FDA has granted a new 510(k) clearance to RenovoRx Inc's (NASDAQ: RNXT) RenovoCath Delivery System.

  • The RenovoCath Delivery System is the device component of the Company's initial product, RenovoGem.

  • The drug/device combination used in RenovoRx's Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy platform is a dual-balloon infusion catheter delivering chemotherapy directly to tumors via arteries.

  • The new design provides more targeted therapy delivery, translating into more effective treatment with fewer side effects.

  • RenovoRx received it's initial 510(k) for the RenovoCath delivery system in 2014.

  • RenovoRx is conducting a Phase 3 trial utilizing the RenovoTAMP platform to evaluate RenovoGem in pancreatic cancer.

  • The study has reached 44% patient enrollment and is expected to involve approximately 200 participants.

  • Related content: Benzinga's Full FDA Calendar.

  • Price Action: RNXT shares are up 64.9% at $13.01 during the premarket session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.